Multiple forces are converging to create a favorable environment for M&A activity involving biopharmaceutical, medtech, and life-sciences-services companies.The industry overviewOur recent analysis reveals renewed optimism and a sharper strategic outlook for dealmaking in the life sciences industry in 2026. After the volatility of the past few years, shaped by geopolitical and macroeconomic tension and regulatory […]
